Instil Bio
77 hedge funds and large institutions have $64M invested in Instil Bio in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 35 closing their positions.
200% more call options, than puts
Call options by funds: $3K | Put options by funds: $1K
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
0.68% less ownership
Funds ownership: 4.6% → 3.92% (-0.68%)
19% less funds holding
Funds holding: 95 → 77 (-18)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
46% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 35
89% less capital invested
Capital invested by funds: $577M → $64M (-$513M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.41M |
| 2 |
Renaissance Technologies
New York
|
+$3.17M |
| 3 |
Two Sigma Investments
New York
|
+$2.85M |
| 4 |
Millennium Management
New York
|
+$1.93M |
| 5 |
Two Sigma Advisers
New York
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$37.1M |
| 2 |
VA
VR Adviser
New York
|
-$19.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.7M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$11.6M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$4.34M |
TIL Hedge Fund Activity: Q4 2022 in Review
77 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q4 2022, worth a combined $64M — down 89% from $577M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of TIL and 19 opened new positions — a net loss of 16 holders — while 19 trimmed existing stakes and 23 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.41M. The largest seller was RA Capital Management, exiting entirely with an estimated $37.1M sold.
- 77 institutional investors held Instil Bio (TIL) as of Q4 2022, down from 95 in Q3 2022.
- Funds reported $64M of Instil Bio stock for Q4 2022, down 89% quarter-over-quarter.
- 19 funds opened new Instil Bio positions in Q4 2022 and 35 closed out, a net change of -16 holders.
- The largest Instil Bio buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.41M added.
- The largest Instil Bio seller in Q4 2022 was RA Capital Management, an estimated $37.1M sold.
Based on aggregated 13F filings for Q4 2022.